82 related articles for article (PubMed ID: 18663559)
1. Taurine in plasma and CSF: a study in healthy male volunteers.
Samuelsson M; Dahl ML; Gupta RC; Nordin C
Amino Acids; 2009 Mar; 36(3):529-33. PubMed ID: 18663559
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
3. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
4. Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers.
Hammarberg A; Beck O; Eksborg S; Jayaram-Lindström N; Lindefeldt A; Andersson M; Brundin L; Reid MS; Franck J
Ther Drug Monit; 2010 Aug; 32(4):489-96. PubMed ID: 20592646
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
6. CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype.
Nordin C; Dahl ML; Eklundh T; Eriksson M; Sjöberg S
Eur Neuropsychopharmacol; 2003 Oct; 13(5):333-5. PubMed ID: 12957331
[TBL] [Abstract][Full Text] [Related]
7. Taurine kinetics assessed using [1,2-13C2]taurine in healthy adult humans.
Rakotoambinina B; Marks L; Badran AM; Igliki F; Thuillier F; Crenn P; Messing B; Darmaun D
Am J Physiol Endocrinol Metab; 2004 Aug; 287(2):E255-62. PubMed ID: 15010336
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
9. Changes in plasma concentration of taurine in stroke.
Ghandforoush-Sattari M; Mashayekhi SO; Nemati M; Ayromlou H
Neurosci Lett; 2011 Jun; 496(3):172-5. PubMed ID: 21514364
[TBL] [Abstract][Full Text] [Related]
10. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
11. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
12. Glutathione in the blood and cerebrospinal fluid: a study in healthy male volunteers.
Samuelsson M; Vainikka L; Ollinger K
Neuropeptides; 2011 Aug; 45(4):287-92. PubMed ID: 21708405
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
14. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
15. [CYP 2D6 activity profile among patients with depression].
Bidziński A; Koszewska I; Turzyńska D; Kalinowski A; Swiecicki L; Dabrowski M; Torbiński J; Burna-Drazkowic E; Fornal S; Gradzka D; Namysłowska M; Puzyński S; Płaźnik A
Psychiatr Pol; 2004; 38(6):1085-92. PubMed ID: 15779672
[TBL] [Abstract][Full Text] [Related]
16. Developmental changes in human liver CYP2D6 expression.
Stevens JC; Marsh SA; Zaya MJ; Regina KJ; Divakaran K; Le M; Hines RN
Drug Metab Dispos; 2008 Aug; 36(8):1587-93. PubMed ID: 18474679
[TBL] [Abstract][Full Text] [Related]
17. Taurine concentration in the brain and in the plasma following intraperitoneal injections.
Lallemand F; De Witte P
Amino Acids; 2004 Mar; 26(2):111-6. PubMed ID: 15042438
[TBL] [Abstract][Full Text] [Related]
18. Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?
Fernández-Santander A; Santiago C; Díez-Durán S; González M; de Castro E; Guijarro J; Bandrés F; Lucia A; Gómez-Gallego F
Hum Psychopharmacol; 2008 Aug; 23(6):533-6. PubMed ID: 18425996
[TBL] [Abstract][Full Text] [Related]
19. Plasma amino acid and whole blood taurine concentrations in cats eating commercially prepared diets.
Heinze CR; Larsen JA; Kass PH; Fascetti AJ
Am J Vet Res; 2009 Nov; 70(11):1374-82. PubMed ID: 19878020
[TBL] [Abstract][Full Text] [Related]
20. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
